Abstract
Positron emission tomography (PET) represents the most sensitive and most specific means for imaging molecular interactions and molecular pathways within the human body. This paper discusses the development of PET methodology. With fruitful collaborations between academic PET centers and the pharmaceutical industry, PET will be valuable in drug discovery and development.
Get full access to this article
View all access options for this article.
References
1.
Jones
T
. The role of positron emission tomography within the spectrum of medical imaging . Eur J of Nucl Med.
1996 ;23 (2 ).
2.
Jones
T
. The imaging science of positron emission tomography . Eur J Nucl Med.
1997 .
3.
Bloomfield
PM
Rajeswaran
S
Spinks
TJ
Hume
SP
Myers
R
Ashworth
S
Clifford
KM
Jones
WF
Byars
LG
Young
J
Andreaco
M
Williams
CW
Lammertsma
AA
Jones
T
. Design and physical characteristics of a small animal positron emission tomograph . Phys Med Biol.
1995 ;40 :1105 –1126 .
4.
Hume
SP
Lammertsma
AA
Myers
R
Rajeswaran
S
Bloomfield
PM
Ashworth
S
Torres
EM
Watson
I
Jones
T
. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease . Neurosci Meth.
1997 .
5.
Cunningham
VJ
Pike
VW
Bailey
D
Freemantle
CAJ
Page
BC
Jones
AKP
Kensett
MJ
Bateman
D
Luthram
SK
Jones
T
. A method of studying pharmacokinetics in man at picomolar drug concentrations . B J Clin Pharmac.
1991 ;32 :167 –172 .
6.
Malizia
A
Forse
G
Haida
A
Gunn
R
Melichar
I
Poole
K
Bateman
D
Fahy
D
Schnorr
L
Brown
D
Rhodes
C
Nutt
DJ
Jones
T
. A new human (psycho)-pharmacology tool: The multiple organs coincidences counter (MOCC) . J Psychopharmacol.
1995 ;9 (4 ): 294 –306 .
7.
Myers
R
Cunningham
VJ
Baily
DI
Jones
T
. Quantification of brain function using PET.
San Diego : Academic Press ; 1996 .